Navigation Links
Small business success spotlighted by USDA at conference
Date:10/15/2010

This press release is available in Spanish.

ChoiceBatter's transformation from a federal laboratory bench technology to a grocery shelf product is among topics that will be discussed here today by U.S. Department of Agriculture (USDA) officials and other participants attending the 17th annual conference of the National Association of Seed and Venture Funds (NASVF).

ChoiceBatter, the brand name for a line of low oil-uptake batters marketed by CrispTek, LLC, of Columbia, Md., is based on a rice-flour formulation created by Fred Shih and Kim Daigle, chemists with the Agricultural Research Service (ARS), USDA's principal intramural scientific research agency.

In tests from 1998-2000, fried chicken, fish and veggies coated in the rice flour batter absorbed up to 50 percent less cooking oil than traditional wheat batters. The rice batter also produced a crisp, golden-brown coating. But existing food companies didn't show any interest in the product, and the recipe languished for several years.

However, following the creation in 2007 of a unique program called the Agricultural Technology Innovation Partnership (ATIP) under the auspices of ARS' Office of Technology Transfer (ARS-OTT), CrispTek licensed the patent in April 2008 and was able to commercially develop and begin selling the rice batter.

"We established this program out of recognition that a federal research agency like ours is limited by mission and resources as to what services it can provide to industry partners who can commercialize and market the outcomes of federal research," said Rick Brenner, Assistant Administrator for ARS-OTT in Beltsville, Md.

"ChoiceBatter is an ideal case study," he added, "because it demonstrates the complexity of turning a federal innovation into a commercial product, as well as illustrates the ATIP program's effectiveness in leveraging necessary assets to fast-track a promising technology towards commercialization."

Under the ATIP program, ARS has signed Partnership Intermediary Agreements with nine regional economic-development entities strategically located around the country. The program is represented nationally by NASVF as the tenth member.

In the case of ChoiceBatter, ARS partnered with ATIP's inaugural member, the Maryland Technology Development Corporation, to provide CrispTek with technical, financial and other support. "CrispTek represents an outstanding early success of this novel program," said Brenner.

At today's conference, Brenner and other presenters will discuss highlights of a forward-looking economic impact assessment, including 2014 sales projections, which ARS and NASVF commissioned based on first-year sales data. The report shows the economic impact resulting from the manufacture and sale of ChoiceBatter in five states: Maryland, Illinois, Iowa, Texas and Louisiana. An additional focus of CrispTek's cooperative research agreement with ARS is expanding that economic impact.


'/>"/>

Contact: Jan Suszkiw
jan.suszkiw@ars.usda.gov
301-504-1630
United States Department of Agriculture -- Research, Education and Economics
Source:Eurekalert

Related medicine news :

1. American Chemical Society Webinar focuses on NSFs small business funding programs
2. Health Care Reform Helps Small Businesses Offer Coverage: Report
3. 16.6 million small business employees could benefit from ACA provisions starting this year
4. Babies Born Late May Face Small Cerebral Palsy Risk
5. Small Amounts of Dark Chocolate May Guard Against Heart Failure
6. Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale
7. Small increases in vaccine cost can cause large gaps in protection
8. Smaller hospitals can provide safe and high-quality surgical care comparable to larger counterparts
9. Small investment could save 11 million African lives
10. Sam's Club Tests Online Small Business Loan Program for Main Street
11. Sex With Recent Smallpox Vaccine Recipient Can Lead to Illness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... , ... Allegheny Health Network (AHN) officials today announced a bold new step ... and services in the greater Pittsburgh region. Starting January 23, patients who call AHN ... that same afternoon. , AHN is the first healthcare provider in ...
(Date:1/19/2017)... ... January 19, 2017 , ... For ... serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a charity ... (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, is ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... at Reproductive Medicine Associates of Connecticut (RMACT) have earned “Top Doctor” awards. ... and Dr. Shaun Williams have each been chosen by their peers for the ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact on ... Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... in order to thrive this year? , The passage of the act means devicemakers ...
(Date:1/19/2017)... ... January 19, 2017 , ... Each year, the Southeastern ... conference where hundreds of surgeons from over fifteen different countries come together to ... breast augmentation to breast reconstruction for breast cancer patients, teaching these ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
(Date:1/19/2017)... FRANCISCO , January 19, 2017 The global  pacemaker ... new report by Grand View Research, Inc. The heightening prevalence of cardiac conditions ... the growth of Pacemaker globally. In addition, technological enhancements in these devices are ... ... Grand View Research Logo ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
Breaking Medicine Technology: